Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment - Part 1: Non-ST-Segment Elevation ACS

Canadian Journal of Cardiology

Volumn 27, Issue 6 SUPPL., 2011, Pages

  Fitchett, David H ^a,b,c   Theroux, Pierre ^d,e   Brophy, James M ^f,g   Cantor, Warren J ^b,h   Cox, Jafna L ^i,j   Gupta, Milan ^k,l,m   Kertland, Heather ^a,b   Mehta, Shamir R ^m,n   Welsh, Robert C ^o,p   Goodman, Shaun G ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CANADIAN HEART RESEARCH CENTRE   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^j DALHOUSIE UNIVERSITY   (Canada)

^k William Osler Health Centre   (Canada)

^l Canadian Cardiovascular Research Network   (Canada)

^m MCMASTER UNIVERSITY   (Canada)

ⁿ HAMILTON HEALTH SCIENCES   (Canada)

^o MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^p UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; LOW MOLECULAR WEIGHT HEPARIN; OCTAPLEX; PRASUGREL; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TICAGRELOR; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BLEEDING; BLOOD PRESSURE REGULATION; CANADA; CULTURAL FACTOR; GLYCEMIC CONTROL; HEALTH CARE DELIVERY; HEART CATHETERIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LIFESTYLE MODIFICATION; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; CANADA; CATHETER ABLATION; DELIVERY OF HEALTH CARE; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 82455216712     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.08.110     Document Type: Review

References (104)

1. Tu J.V., Austin P.C., Filate W.A., et al. Outcomes of acute myocardial infarction in Canada. Can J Cardiol 2003, 19:893-901.
2. Heart Disease and Stroke, Vol. 1, Chapter 12, 2011 Healthy People 2010, Accessed September 30, 2011. http://www.healthypeople.gov/Document/tableofcontents.htm#volume1.
3. 2009 Tracking Heart Disease and Stroke in Canada Public Health Agency of Canada, Accessed September 30, 2011. http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/index-eng.php.
4. Filate W.A., Johansen H.L., Kennedy C.C., Tu J.V. Regional variations in cardiovascular mortality in Canada. Can J Cardiol 2003, 19:1241-1248.
5. Tanuseputro P., Manuel D.G., Leung M., Nguyen K., Johansen H. Risk factors for cardiovascular disease in Canada. Can J Cardiol 2003, 19:1249-1259.
6. Canadian Community Health Survey 2007/2008, age 12+ except for weight which is age 18+. A Perfect Storm of Heart Disease Looming on Our Horizon: January 25, 2010 2010, 2010 Heart and Stroke Foundation Annual Report on Canadians' Health. HSFC, Accessed September 30, 2011. http://www.heartandstroke.com/atf/cf/%7B99452D8B-E7F1-4BD6-A57D-B136CE6C95BF%7D/Jan23_EN_ReportCard.pdf.
7. Wijeysundera H.C., Machado M., Farahati F., et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010, 303:1841-1847.
8. Tu J.V., Nardi L., Fang J., Liu J., Khalid L., Johansen H. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994-2004. CMAJ 2009, 180:E118-E125.
9. Ko D.T., Newman A.M., Alter D.A., et al. Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. Can J Cardiol 2010, 26:129-134.
10. Fitchett D.H., Theroux P., Brophy J.M., et al. Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment - part 2: ST-segment elevation myocardial infarction. Can J Cardiol 2011, 27(suppl):S402-S412.
11. Jackevicius C.A., Alter D., Cox J., et al. Acute treatment of myocardial infarction in Canada 1999-2002. Can J Cardiol 2005, 21:145-152.
12. Pilote L., Beck C.A., Karp I., et al. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. Can J Cardiol 2004, 20:61-67.
13. Pilote L., Merrett P., Karp I., et al. Cardiac procedures after an acute myocardial infarction across nine Canadian provinces. Can J Cardiol 2004, 20:491-500.
14. Yan A.T., Yan R.T., Tan M., et al. In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. Am J Cardiol 2005, 96:913-916.
15. Yan A.T., Yan R.T., Tan M., et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 2007, 28:1072-1078.
16. Yan R.T., Yan A.T., Tan M., et al. Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. Am Heart J 2006, 152:676-683.
17. Yan R.T., Yan A.T., Tan M., et al. Age-related differences in the management and outcome of patients with acute coronary syndromes. Am Heart J 2006, 151:352-359.
18. LeLorier J., Bell A., Bougher D.J., Cox J.L., Turpie A.G. Drug reimbursement policies in Canada--need for improved access to critical therapies. Ann. Pharmacother 2008, 42:869-873.
19. Guertin J.R., Jackevicius C.A., Cox J.L., et al. The potential economic impact of restricted access to angiotensin-receptor blockers. CMAJ 2011, 183:E180-E186.
20. Demers V., Melo M., Jackevicius C., et al. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ 2008, 178:405-409.
21. Sheehy O., LeLorier J., Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ 2008, 178:413-420.
22. Jackevicius C.A., Tu J.V., Demers V., et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med 2008, 359:1802-1810.
23. Peterson E.D., Roe M.T., Mulgund J., et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006, 295:1912-1920.
24. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction- executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007, 50:652-726.
25. Wright S.A., Anderson J.L., Adams C.D., et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction (updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011, 57:1920-1959.
26. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1598-1660.
27. Roe M.T., Peterson E.D., Newby L.K., et al. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2006, 151:1205-1213.
28. Bell A.D., Roussin A., Cartier R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 2011, 27(suppl):S1-S59.
29. Canto J.G., Shlipak M.G., Rogers W.J., et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000, 283:3223-3229.
30. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. J Am Coll Cardiol 2007, 50:2173-2195.
31. Keller T., Zeller T., Peetz D., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009, 361:868-877.
32. Sanchis J., Bodi V., Nunez J., et al. New risk score for patients with acute chest pain, non--ST-segment deviation, and normal troponin concentrations. A comparison with the TIMI risk score. J Am Coll Cardiol 2006, 46:443-449.
33. de Winter R.J., Windhausen F., Cornel J.H., et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005, 353:1095-1104.
34. Steg P.G., FitzGerald G., Fox K.A. Risk stratification in non-ST-segment elevation acute coronary syndromes: troponin alone is not enough. Am J Med 2009, 122:107-108.
35. Antman E.M., Cohen M., Bernink P.J.L.M., et al. The TIMI risk score for unstable angina / non-ST elevation MI. JAMA 2000, 284:835-842.
36. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004, 291:2727-2733.
37. Pelliccia F., Salvini P., Cartoni D., et al. Frequency and clinical correlates of changes in thrombolysis in myocardial infarction risk score during observation period at emergency department in "low-risk" patients with acute chest pain. Am J Cardiol 2006, 97:781-784.
38. Zia M.I., Goodman S.G., Peterson E.D., et al. Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. Can J Cardiol 2007, 23:1073-1079.
39. Fitchett D.H., Borgundvaag B., Cantor W., et al. Non ST segment elevation acute coronary syndromes: a simplified risk-orientated algorithm. Can J Cardiol 2006, 22:663-677.
40. Mehta S.R., Granger C.B., Boden W.E., et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009, 360:2165-2175.
41. Jedrzkiewicz S., Goodman S.G., Yan R.T., et al. Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. Can J Cardiol 2009, 25:e370-e376.
42. Elbarouni B., Goodman S.G., Yan R.T., et al. Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. Am Heart J 2009, 158:392-399.
43. Yan A.T., Yan R.T., Tan M., et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med 2007, 167:1009-1016.
44. Cohen M.G., Filby S.J., Roe M.T., et al. The paradoxical use of cardiac catheterization in patients with non-ST-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guidelines (CRUSADE) Quality Improvement Initiative. Am Heart J 2009, 158:263-270.
45. Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002, 23:1190-1201.
46. Lee C.H., Tan M., Yan A.T., et al. Use of cardiac catheterization for non-ST-segment elevation acute coronary syndromes according to initial risk: reasons why physicians choose not to refer their patients. Arch Intern Med 2008, 168:291-296.
47. Bagnall A.J., Yan A.T., Yan R.T., et al. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010, 3:530-537.
48. Moscucci M., Fox K.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003, 24:1815-1823.
49. Subherwal S., Bach R.G., Chen A.Y., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 2009, 119:1873-1882.
50. Mehran R., Pocock S.J., Nikolsky E., et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010, 55:2556-2566.
51. Mathews R., Peterson E.D., Chen A.Y., et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION registry(R)-GWTG. Am J Cardiol 2011, 107:1136-1143.
52. LaPointe N.M., Chen A.Y., Alexander K.P., et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. Arch Intern Med 2007, 167:1539-1544.
53. Wong J.A., Goodman S.G., Yan R.T., et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. Eur Heart J 2009, 30:549-557.
54. Chase A.J., Fretz E.B., Warburton W.P., et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008, 94:1019-1025.
55. Jolly S.S., Yusuf S., Cairns J., et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011, 377:1409-1420.
56. Cantor W.J., Mahaffey K.W., Huang Z., et al. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv 2007, 69:73-83.
57. Yusuf S., Mehta S.R., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476. The Fifth Organisation to Assess Strategies in Acute Ischemic Syndromes Investigators.
58. effects of clopidogrel in addition to ASA in patients with acute coronay syndromes without ST segment elevation. N Engl J Medicine 2001, 345:494-502. The clopidogrel in unstable angina to prevent recurrent events trial investigators.
59. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
60. Held C., Asenblad N., Bassand J.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011, 57:672-684.
61. Bertrand O.F., Rao S.V., Pancholy S., et al. Transradial approach for coronary angiography and interventions: results of the first international transradial practice survey. JACC Cardiovasc Interv 2010, 3:1022-1031.
62. Fitchett D., Eikelboom J., Fremes S., et al. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol 2009, 25:683-689.
63. Cantor W.J., Goodman S.G., Cannon C.P., et al. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. Am Heart J 2005, 149:275-283.
64. Bavry A.A., Kumbhani D.J., Rassi A.N., Bhatt D.L., Askari A.T. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006, 48:1319-1325.
65. Fox K.A., Clayton T.C., Damman P., et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010, 55:2435-2445.
66. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol 1998, 82:731-736.
67. Ryan J.W., Peterson E.D., Chen A.Y., et al. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation 2005, 112:3049-3057.
68. Bassand J.P. The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes. Eur Heart J 2008, 10(suppl C):C22-C29.
69. Petersen J.L., Mahaffey K.W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004, 292:89-96.
70. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial. JAMA 2004, 292:45-54. The Synergy Trial Investigators.
71. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
72. Mehta S.R., Tanguay J.-F., Eikelboom J.W., et al. Double dose versus standard dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010, 376:1233-1243.
73. Mehta S.R., Bassand J.P., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942. CURRENT-OASIS 7 Investigators.
74. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
75. Peters R.J., Mehta S.R., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108:1682-1687.
76. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189-198.
77. Boersma E., Westerhout C.M. Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials. Curr Opin Investig Drugs 2004, 5:313-319.
78. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009, 360:2176-2190.
79. Wang T.Y., White J.A., Tricoci P., et al. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation 2011, 123:722-730.
80. Stone G.W., Bertrand M.E., Moses J.W., et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA 2007, 297:591-602.
81. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
82. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
83. Varenhorst C., James S., Erlinge D., et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009, 30:1744-1752.
84. Rao R.V., Goodman S.G., Yan R.T., et al. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. Am Heart J 2009, 157:642-650.
85. Bell A.D., Roussin A., Cartier R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 2011, 27:208-221.
86. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
87. James S.K., Roe M.T., Cannon C.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011, 342:d3527.
88. Gurbel P.A., Bliden K.P., Butler K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009, 120:2577-2585.
89. Gurbel P.A., Bliden K.P., Butler K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010, 121:1188-1199.
90. Henriksson M., Nikoloc E., Janzon M., et al. Long term costs and health outcomes of treating acute coronary syndrome patients with ticagrelor based on the EU label- Cost effectiveness analysis based on the PLATO study. Value in Health 2011, 14:A40.
91. Freemantle N., Cleland J.G., Young P., et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999, 1730-1737.
92. Cairns J., Gent M., Singer J., et al. Aspirin, sulphinpyrazone or both in unstable angina: results of a Canadian multicentre trial. New Engl J Med 1985, 313:1369-1375.
93. Theroux P., Waters D., Qiu S., et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88:2045-2048.
94. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
95. Cannon C.P., McCabe C.H., Wilcox R.G., et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT)- TIMI 22 trial. Am J Cardiol 2002, 89:860-861.
96. LaRosa J.C., Grundy S.M., Waters D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Eng J Med 2005, 352:1425-1435.
97. Dagenais G.R., Pogue J., Fox K., Simoons M.L., Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006, 368:581-588.
98. Flather M.D., Lonn E.M., Yusuf S. Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: evidence from the larger randomized controlled trials. J Cardiovasc Risk 1995, 2:423-428.
99. Hall A.S., Murray G.D., Ball S.G. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Lancet 1997, 349:1493-1497.
100. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
101. Yusuf S., Teo K., Anderson C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174-1183.
102. McMurray J., Solomon S., Pieper K., et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006, 47:726-733.
103. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005, 46:425-431.
104. Phrommintikul A., Kuanprasert S., Wongcharoen W., et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011, 32:1730-1735.